| Product | Developer | Development stage at time of guidance |
|---|---|---|
| Ad26.COV2.S | Janssen-Cilag International N.V. | Non-clinical phase |
| Ad5-nCoV vaccine | Cansino Biotech | Clinical phase |
| Adjuvanted whole virion inactivated vaccine | Sinovac Life Sciences Co | Non-clinical phase |
| ChAdOx1-SARS-CoV-2 | Vaccitech/AstraZeneca | Clinical phase |
| Coronavirus-like particle (COVLP) | Medicago | Non-clinical phase |
| CVnCoV, CV07050101 vaccine | Curevac | Non-clinical phase |
| Herpes simplex virus vector tetravalent SARS-CoV-2 vaccine | Krystal Bio | Non-clinical phase |
| LNP-saRNA CoVid19 vaccine | VacEquity Global Health/Imperial College London | Clinical phase |
| LUNAR-COV19 mRNA vaccine | Arcturus Therapeutics | Clinical phase |
| mRNA SARS-CoV-2 vaccine | Biontech | Non-clinical phase |
| mRNA-1273 SARS-CoV-2 vaccine | Moderna | Non-clinical phase |
| MV-SARS-CoV-2 vaccine | Themis Bioscience GmbH/Merck Sharp & Dohme (MSD) | Non-clinical phase |
| NVX-CoV-2 rS | Novavax | Non-clinical phase |
| Protein nanoparticle vaccine | Emergex Vaccines Holding Ltd | Non-clinical phase |
| rVSVΔG-SARS-CoV-2 live attenuated | Merck Sharp & Dohme (MSD)/IAVI | Non-clinical phase |
| SARS-CoV-2 DNA vaccine | Inovio | Non-clinical phase |
| SARS-Cov-2 vaccine | Queensland University/Seqirus/CSL | Non-clinical phase |
| SARS-CoV-2 vaccine recombinant, adjuvanted | Sanofi Pasteur | Non-clinical phase |
| S-trimer subunit vaccine | Clover Biopharma | Clinical phase |
| Subunit vaccine adjuvanted MVC-COV1901 | Medigen | Non-clinical phase |
| VLA 2001 vaccine | Valneva | Non-clinical phase |
| Protein vaccine adjuvanted | Kentucky Bioprocessing, Inc | Non-clinical phase |
| DNA Plasmid vaccine | Takis S.r.l., Rottapham Biotech | Non-clinical phase |
| Gam-COVID-Vac | The Gamaleya National Centre of Epidemiology and Microbiology | Clinical phase |
| MRT5500 mRNA vaccine | Sanofi / Translate Bio | Non-clinical phase |
| PB-206 | HIPRA | Non-clinical phase |
| UB-612 | Vaxxinity (Covaxx) / UBI (United Biomedical, Inc.) | Clinical phase |
| MVA-SARS-2-S and MVA-SARS-2-ST | IDT-Biologika / German Center for Infection Research (DZIF) | Clinical phase |
| GBP510 | Sk Bioscience Co. Ltd | Clinical phase |
| FINCoVac 2.0 vaccine | Rokote Laboratories Finland Oy | Non-clinical phase |
| GRAd-COV2 | Reithera S.r.l. | Clinical phase |
| GSK&CV SARS-COV-2 vaccine (2nd generation) | GSK and CureVac | Clinical phase |
| Prime‐2‐CoV | Speransa Therapeutics | Clinical phase |
| Vaxzevria-AZD-2816 | AstraZeneca | Clinical phase |
| RVX-13 | RocketVax AG | Non-clinical phase |
| ABNCoV2 | Bavarian Nordic AS | Clinical phase |
| VB10.2210 | Nykode Therapeutics | Clinical phase |
| PHH-1V | Laboratorios HIPRA S.A. | Clinical phase |
| ISR52 | ISR Vaccine AB | Non-clinical phase |
| INO-4800 | Inovio | Clinical phase |
| ARCT-154 | Arcturus Therapeutics Europe B.V. | Clinical phase |
| Ad5-nCoV-IH | Cansino Biotech | Clinical phase |
| MVC-COV1901 | Medigen Vaccine Biologics Corp. | Clinical phase |
| Dellera, mRNA vaccine | Fondo Ricerca Medica S.r.l. | Clinical phase |
| CV0501 | CureVac and GSK | Clinical phase |
| COVI-Liv | Bilthoven Biologicals B.V. | Clinical phase |
| CD40.RBDv, CD40.Pan.CoV |
LinKinVax | Non-clinical phase |
| MVA-CoV2-S(3P) | Biofabri S.L. | Non-clinical phase |
| Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
|---|---|---|---|
| A64-DP | BCN Peptides SA | Immunomodulator | Non-clinical phase |
| Acalabrutinib | Acerta Pharma BV / AstraZeneca | Immunomodulator | Clinical phase |
| Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | Alliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda) | Antiviral | Clinical phase |
| APN01 | Apeiron Biologics | Immunomodulator | Clinical phase |
| Apremilast | Amgen Europe BV | Immunomodulator | Clinical phase |
| AZD7442 | AstraZeneca | Antiviral (monoclonal antibody) | Non-clinical phase |
| Baricitinib | Eli Lilly | Immunomodulator | Clinical phase |
| CD24Fc | Oncoimmune Inc | Immunomodulator | Clinical phase |
| CHAG-COVID19-CA | ChimAgents | Challenge agent for human infection models | Non-clinical phase |
| Chloroquine | Oxford University | Other therapeutic | Clinical phase |
| Chloroquine and hydroxychloroquine cyclops DPI | PureIMS | Other therapeutic | Clinical phase |
| Copper chloride | ACOM | Antiviral | Clinical phase |
| CT-P59 | Celltrion | Antiviral (monoclonal antibody) | Non-clinical phase |
| Danoprevir | Ascletis Pharmaceuticals Co Ltd | Antiviral | Clinical phase |
| Eculizumab | Alexion | Immunomodulator | Clinical phase |
| Emapalumab and anakinra | Swedish Orphan Biovitrum AB (SOBI) | Immunomodulator | Clinical phase |
| FAV00B | Farmak International Holding GmbH | Antiviral | Non-clinical phase |
| Favipiravir | Glenmark Pharmaceuticals Ltd | Antiviral | Clinical phase |
| Gimsilumab | Roivant | Immunomodulator | Clinical phase |
| Kamada Anti-SARS-CoV-2 | Kamada Ireland Ltd | Immunoglobulin | Non-clinical phase |
| Larifan Plus | Auramed Ltd | Antiviral | Non-clinical phase |
| LY-CoV555 (LY3819253) and LY-CoV016 (LY3832479) | Eli Lilly | Antiviral (monoclonal antibody) | Non-clinical phase |
| M5049 | Merck Healthcare | Immunomodulator | Non-clinical phase |
| Mavrilimumab | Kiniksa Pharmaceuticals | Immunomodulator | Clinical phase |
| Meplazumab | Jiangsu Pacific Meinuoke Biopharmaceutical Co Ltd | Antiviral (monoclonal antibody) | Clinical phase |
| MK-4482 | Ridgeback Biotherapeutics LP/Merck Sharp & Dohme (Europe) Inc | Antiviral | Non-clinical phase |
| Otilimab | GSK | Immunomodulator | Clinical phase |
| PF-07304814 | Pfizer | Antiviral | Non-clinical phase |
| Raloxifene | Dompé | Antiviral | Non-clinical phase |
| Ravulizumab | Alexion | Other therapeutics | Clinical phase |
| RBT-9 | Renibus Therapeutics Inc | Antiviral | Clinical phase |
| REGN10933, REGN10987, REGN10989 | Regeneron UK | Antiviral (monoclonal antibody) | Non-clinical phase |
| Remdesivir | Gilead | Antiviral | Clinical phase |
| RESP301 | Thirty Respiratory Limited (30 Technology) | Antiviral | Non-clinical phase |
| Sarilumab | Sanofi Aventis | Immunomodulator | Clinical phase |
| Siltuximab | EUSApharma | Immunomodulator | Clinical phase |
| Tocilizumab | Roche | Immunomodulator | Clinical phase |
| UNI911 | Union Therapeutics | Antiviral | Clinical phase |
| VIR-7831, VIR-7832 | Vir Biotechnology/GSK | Antiviral (monoclonal antibody) | Clinical phase |
|
SNG001
|
Synairgen Research Limited | Immunomodulator | Clinical phase |
| VRP-033 | Venus Pharma GmbH | Immunomodulator | Non-clinical phase |
| BRII-196, BRII-198 | Brii Biosciences | Antiviral (monoclonal antibody) | Non-clinical phase |
| SCTA01 | Sinocelltech Ltd. | Antiviral (monoclonal antibody) | Clinical phase |
| Itolizumab | Biocon Biologics Limited | Immunomodulator | Clinical phase |
| BI 764198 | Boehringer Ingelheim International GmbH | Other therapeutic | Clinical phase |
| 4P021 | 4P-Pharma | Antiviral | Non-clinical phase |
| Masitinib mesylate | AB Science | Antiviral | Non-clinical phase |
| EX-14870 | Boehringer Ingelheim International BmBH | Antiviral | Non-clinical phase |
| 2-DEOXY-D-GLUCOSE | Dermin Sp. Z.0.0 | Other therapeutic |
Non-clinical Phase Clinical phase |
| Emiplacel | Biopharma Excellence GmbH | Other therapeutic | Clinical phase |
| AT-527 | Roche | Antiviral | Clinical phase |
| ABBV-47D11 | AbbVie | Antiviral | Clinical phase |
| Aviptadil | Relief Therapeutics Holding S.A | Other therapeutic | Clinical phase |
| AR-711 | Aridis Pharmaceuticals, Inc. | Antiviral (monoclonal antibody) | Non-clinical phase |
| Colchicine | Pharmascience Inc. (PMS) / Montreal Health Institute (MHI) | Immunomodulator | Clinical phase |
| CoviFab | Inmunova S.A. / mAbxience | Antiviral | Clinical phase |
| Trimodulin (human IgM, IgA, IgG solution) | Biotest AG | Immunomodulator | Clinical phase |
| MK-7110 | Merck Sharp & Dohme (MSD) / Merck & Co. | Immunomodulator | Clinical phase |
| Camostat | Daewoong | Antiviral | Clinical phase |
| Bemcentinib | BergenBio | Antiviral | Clinical phase |
| Vidofludimus calcium (IMU–838) | Immunic AG | Immunomodulator / Antiviral | Clinical phase |
| Vilobelimab | InflaRx GmbH | Immunomodulator | Clinical phase |
| FBR-002 | Fab'entech | Antiviral (monoclonal antibody) | Clinical phase |
| BMS986414 and BMS986413 | Rockefeller University and Bristol Myers Squibb | Antiviral (monoclonal antibody) | Clinical phase |
| Proxalutamide | Suzhou Kintor Pharmaceuticals / Applied Biology | Other therapeutic | Clinical phase |
| Calcifediol | Vifor Fresenius Medical Care Renal Pharma France | Other therapeutic | Clinical phase |
| Lenzilumab | Humanigen | Immunomodulator | Clinical phase |
| Azelastine | Ursapharm | Immunomodulator | Clinical phase |
| Opaganib hydrochloride | RedHill Biopharma | Other therapeutic | Clinical phase |
| MAD0004J08 | Menarini Ricerche S.p.A. | Antiviral (monoclonal antibody) | Clinical phase |
| C21 | Vicore Pharma | Immunomodulator | Clinical phase |
| nezulcitinib | Theraevance Biopharma | Immunomodulator | Clinical phase |
| Imlifidase (Idefirix) | Hansa Biopharma AB | Immunomodulator | Clinical phase |
| WP 1122 | Wpd Pharmaceuticals Sp z o.o | Other therapeutic | Non clinical phase |
| RGB-22 | Chemical Works Of Gedeon Richter PLC | Antiviral | Non-clinical phase |
| XAV-19 | Xenothera | Antiviral | Clinical phase |
| Imatinib Mesilate | Exvastat | Immunomodulator | Clinical phase |
| PF-07321332 | Pfizer | Antiviral | Clinical phase |
| Fostamatinib | Rigel | Immunomodulator | Clinical phase |
| ADG20 | Adagio Therapeutics | Immunomodulator | Clinical phase |
| Interferon alfa (INF-alpha), chimeric | Genova Inc | Other therapeutic | Non-clinical phase |
| XVR011 | Exevir Bio | Antiviral | Clinical phase |
| N,N’-bis[2-(1H-imidazol-2-yl)ethyl]pentanediamide | Treamid GmbH | Immunomodulator | Clinical phase |
| S-217622B | Shionogi B.V. | Antiviral | Clinical phase |
| CYCLOBENZAPRINE HYDROCHLORIDE | M-Squared Consulting S.r.l. | Other therapeutic | Clinical phase |
| F004 | HWI Analytik GmbH | Antiviral | Non-clinical phase |
| XC221GI | Valenta Pharmaceuticals JSC | Antiviral | Clinical phase |
| RMD-101 | Remedy Biologics Limited | Antiviral | Non-clinical phase |
| PRO75 | Evotec International GmbH | Antiviral (monoclonal antibody) | Non-clinical phase |
| Reparixin | Dompé farmaceutici s.p.a | Immunomodulator | Clinical phase |
| Ensovibep | Novartis | Antiviral | Clinical phase |
| Ivermectin | Hwi Pharma Services GmbH | Antiviral | Clinical phase |
| HH-120 | Huahui Health Ltd. | Antiviral | Clinical phase |
| ASUNERCEPT | Apogenix AG | Immunomodulator | Clinical phase |
| Regdanvimab | Celltrion Healthcare Hungary Kft. | Antiviral (monoclonal antibody) | Clinical phase |
| Plitidepsin | Pharma Mar, S.A. | Antiviral | Clinical phase |
| Ronapreve | Regeneron | Antiviral (monoclonal antibody) | Clinical phase |
| Cetylpyridinium chloride | Veristat Spain S.L. | Antiviral | Clinical phase |
| Olokizumab | R-Pharm CJSC | Antiviral (monoclonal antibody) | Clinical phase |
| Aprotinin | Gerencia De Atención Integrada De Ciudad Real | Antiviral | Clinical phase |
| Niclosamide nasal spray | Union Therapeuthics | Antiviral | Clinical phase |
| AZD7518 (AZD3152, AZD3959) | AstraZeneca AB | Antiviral (monoclonal antibody) | Clinical phase |
| Sabizabulin | Veru Inc. | Antiviral | Clinical phase |
| TATX-03 (21-F2, 22-F7, 23-H7, 2-A6) | Talem Therapeutics LLC | Antiviral (monoclonal antibody) | Clinical phase |
| GS-5245 | Gilead Sciences Ireland Unlimited Company | Antiviral | Clinical phase |
| SPK001 | SpikImm | Antiviral (monoclonal antibody) | Clinical phase |
| BC 007 (GS 522 or ARC183) | Berlin Cures | Immunomodulator | Clinical phase |
| Arylacenamide | Meletios Therapeutics | Antiviral and immunomodulator |
Clinical phase |
| MK-7845 | Merck | Antiviral | Non-clinical phase |
| Bemnifosbuvir hemisulfate | Atea Pharmaceuticals Inc | Antiviral | Clinical phase |
| ALG-097558 | Aligos Belgium BV | Antiviral | Non-clinical phase |